PDCD1 and hereditary sensory and autonomic neuropathy: The incidence, risk, clinical characteristics and mechanism of CIP for anti-PD-1/PD-L1 monotherapy or a combination with other therapies (radiotherapy, chemotherapy or targeted therapy) may differ, which might influence the subsequent treatment options and prognosis of CIP (12).